HC Wainwright Has Positive Estimate for MBRX Q3 Earnings

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Investment analysts at HC Wainwright increased their Q3 2025 earnings per share estimates for Moleculin Biotech in a research report issued to clients and investors on Wednesday, August 13th. HC Wainwright analyst S. Nik now forecasts that the company will earn ($0.23) per share for the quarter, up from their prior forecast of ($0.32). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share. HC Wainwright also issued estimates for Moleculin Biotech’s Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.85) EPS and FY2026 earnings at ($0.85) EPS.

Moleculin Biotech Stock Performance

Shares of MBRX stock opened at $0.68 on Friday. The stock’s 50 day simple moving average is $0.58 and its two-hundred day simple moving average is $0.89. Moleculin Biotech has a 1 year low of $0.25 and a 1 year high of $3.65.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10).

Insider Activity at Moleculin Biotech

In other Moleculin Biotech news, CEO Walter V. Klemp purchased 675,675 shares of Moleculin Biotech stock in a transaction dated Monday, June 23rd. The shares were purchased at an average cost of $0.37 per share, for a total transaction of $249,999.75. Following the completion of the acquisition, the chief executive officer owned 743,607 shares in the company, valued at $275,134.59. This represents a 994.63% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Jonathan P. Foster acquired 270,270 shares of the company’s stock in a transaction that occurred on Monday, June 23rd. The stock was purchased at an average cost of $0.37 per share, for a total transaction of $99,999.90. Following the purchase, the chief financial officer owned 287,587 shares of the company’s stock, valued at $106,407.19. This represents a 1,560.72% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Moleculin Biotech stock. Armistice Capital LLC raised its stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) by 293.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,250,000 shares of the company’s stock after acquiring an additional 932,414 shares during the quarter. Armistice Capital LLC owned approximately 8.93% of Moleculin Biotech worth $1,217,000 at the end of the most recent reporting period. Institutional investors own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.